The 2017 Israeli Drug Basket has been published, and Imbruvica has been included and approved for 3rd line treatment of Waldenstrom's Macroglobulinemia. Dr. Treon's contribution to this effort included his presentations, recommendations, and consultations with several local teams, which helped lead to emphasizing the importance of Imbruvica as a transforming agent for the treatment of symptomatic WM patients.

The healthcare basket includes all services, medications, medical equipment, and devices to which the insured are entitled to receive according to the National Health Insurance Act of 1994, which allows any resident of the State of Israel to receive health care through HMOs.